Good question

kindly take a look at these articles:

Article Prothrombotic phenotype in COVID-19 severe patients

Article COVID-19 and Thrombotic or Thromboembolic Disease: Implicati...

There is evidence of direct invasion of endothelial cells by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, potentially leading to cell injury. Other sources of endothelial injury include intravascular catheters and mediators of the acute systemic inflammatory response such as cytokines (eg, interleukin [IL]-6) and other acute phase reactants . A number of changes in circulating prothrombotic factors have been reported or proposed in patients with severe COVID-19 :

Elevated factor VIII

•Elevated fibrinogen

•Circulating prothrombotic microparticles

•Neutrophil extracellular traps (NETs)

From link below:

https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-hypercoagulability

Coronavirus disease 2019 (COVID-19): Hypercoagulability

Ali Haider Mohammed

We know Covid 19 as a respiratory illness, but as more reports come in about the varied presentations of disease, we know that it is an inflammatory state where disseminated intravascular coagulopathy (DIC) different from that seen in sepsis leads to high mortality. The most typical haematological findings seen in patients with COVID-19 and coagulopathy are an increased D-dimer concentration, modest decrease in platelet counts, and prolonged prothrombin time.

In COVID-19, a systemic and pulmonary hypercoagulable state has been proposed independent of hypoxia, ARDS, and sepsis-

1. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Dennis McGonagle, James S O’Donnell, Kassem Sharif, Paul Emery, Charles Bridgewood

2. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy [published online ahead of print, 2020 Apr 23]. Thromb Res. 2020;191:9‐14. doi:10.1016/j.thromres.2020.04.024

3. Joly, B.S., Siguret, V. & Veyradier, A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med (2020). https://doi.org/10.1007/s00134-020-06088-1

4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3